CINGW
Cingulate Inc. WarrantsNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-1.73
Beta
-0.81
52W High
$0.17
52W Low
$0.02
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cingulate Inc. Warrants
Cingulate Inc. Warrants offer a compelling investment opportunity tied to a biopharmaceutical company focused on developing groundbreaking therapies for Attention Deficit Hyperactivity Disorder (ADHD) and related conditions. The company is progressing with a strong lead product aimed at improving treatment efficacy and patient tolerability, thereby addressing critical gaps in a rapidly expanding market. With a robust pipeline and strategic growth plans, Cingulate positions itself as a promising candidate for institutional investors looking to enhance their portfolios within the healthcare sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-9.74M |
| EBITDA | $-23.66M |
| Operating Margin | 0.00% |
| Return on Equity | -225.10% |
| Return on Assets | -69.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.58 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $12.94M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 5/25/2026